Camrelizumab: all 354 studies that test it
Page 3 of 4. Open to participants first (126), then studies with results posted, then the rest; newest registration first within each.
- Camrelizumab Combined With Radiotherapy and Chemotherapy for the Treatment of Recurrent or Metastatic Cervical CancerStatus unknownNCT04884906Phase 2
- SBRT/LDRT in Combination With Camrelizumab and Apatinib in Metastatic Non-small Cell Lung Cancer Patient Previously Treated With PD-1/L1 Inhibitor and ChemotherapyStatus unknownNCT04878107Phase 2
- An Exploratory Clinical Study of SHR6390 and SHR1020 in the Treatment of Esophageal Squamous Cell Carcinoma After Progression on PD-1 AntibodyStatus unknownNCT04866381Phase 2
- A Neoadjuvant Hepatocellular Carcinoma Study of Camrelizumab in Combination With Apatinib and OxaliplatinStatus unknownNCT04850040Phase 2
- Efficacy and Safety of Combinition of Camrelizumab in Second-line Neoadjuvant Chemotherapy and Adjuvant TherapyStatus unknownNCT04848454Phase 2
- Apatinib Combined With SHR-1210 as Second-line Treatment in Solid Tumors With Only Liver MetastasesStatus unknownNCT04832204Phase 2
- Fluzoparib Combined With Camrelizumab for Maintenance Treatment of Locally Advanced Non-small Cell Lung CancerStatus unknownNCT04828395Phase 2
- Microwave Ablation Combined With Camrelizumab in the Treatment of Early Breast CancerCompletedNCT04805736Phase 2
- SHR-1210 in Combination With Anlotinib in Patients With Advanced or Metastatic Esophageal Squamous Cell CancerStatus unknownNCT04797507Phase 2
- a Study of SHR1210 in Combination With Paclitaxel-albumin and Carboplatin in Extensive Stage Small Cell Lung CancerStatus unknownNCT04790539Phase 2
- Camrelizumab Combined With SRT/WBRT and Chemotherapy in Patients With Brain Metastases of Driven Gene-negative NSCLCCompletedNCT04768075Phase 3
- A Study of Camrelizumab Combined With Chemotherapy as Neoadjuvant Therapy in Adcanced Esophageal Squamous Cell Carcinoma (ESCC)Status unknownNCT04767295Phase 2
- Camrelizumab Combined With Radiotherapy for Adjuvant Treatment of Esophageal Squamous Cell Carcinoma After SurgeryStatus unknownNCT04741490Not applicable
- Cryoablation Combined With Camrelizumab and Apatinib in Advanced Hepatocellular CarcinomaStatus unknownNCT04724226Phase 2
- Camrelizumab Combined With Apatinib and Capecitabine in Patients With Advanced Biliary Tract Cancer.CompletedNCT04720131Phase 2
- PD-1 Inhibitors Combined With VEGF Inhibitors for Locally Advanced dMMR/MSI-H Colorectal CancerStatus unknownNCT04715633Phase 2
- Safety and Efficacy of Camrelizumab for High-risk NMIBC Failing BCG TreatmentActive, not recruitingNCT04706598Phase 1/2
- The Conversion Therapy of Chemotherapy Plus Camrelizumab in Metastatic Gastric CancerCompletedNCT04694183Phase 2
- Camrelizumab Combined With Apatinib ,Carboplatin and Etoposide in Participants With ES-SCLCStatus unknownNCT04683198Phase 2
- A Study of SHR-1210± SHR-1020 Versus Chemotherapy in Patients With Recurrent or Metastatic Cervical CancerCompletedNCT04680988Phase 2
- Neoadjuvant Study of Camrelizumab Plus Chemotherapy in Triple Negative Breast Cancer (TNBC)Status unknownNCT04676997Phase 2
- A Prospective, Randomized, Double-blinded, Multi-center Clinical Trial to Evaluate the Efficiency and Safety of Anti-PD1 Antibody (Camrelizumab) Combined With Paclitaxel(Albumin Bound) and Gemcitabine as First-line Therapy in Patients With Metastatic Pancreatic CancerStatus unknownNCT04674956Phase 3
- Camrelizumab Plus Apatinib for Advanced Non-Squamous NSCLC Previously Treated With First-Line ImmunotherapyStatus unknownNCT04670913Phase 2
- Study of First-line Camrelizumab With or Without Chemotherapy for Advanced Esophageal Squamous Cell CancerStatus unknownNCT04654403Not applicable
- Apatinib Plus Camrelizumab in Patients With Previously Treated Advanced Biliary Tract CancerCompletedNCT04642664Phase 2
- A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or AblationActive, not recruitingNCT04639180Phase 3
- A Study to Evaluate SHR-1210 in Combination With Famitinib Plus Chemotherapy in Subjects With NSCLC.TerminatedNCT04619433Phase 3
- A Study of Camrelizumab Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)CompletedNCT04613674Phase 3
- Camrelizumab and Apatinib for Neoadjuvant Therapy in Thyroid CancerStatus unknownNCT04612894Phase 2
- Study of Camrelizumab (SHR-1210) and Apatinb Based Therapies for Alpha-fetoprotein (AFP)-Producing Gastric Cancer or Gastroesophageal Junction AdenocarcinomaStatus unknownNCT04609176Phase 2
- Anti-PD-1 Antibody in the Treatment of Patients With Malignant Melanoma of the Female Genital TractStatus unknownNCT04593485Phase 2
- Apatinib and Camrelizumab in Recurrent or Metastatic Nasopharyngeal Carcinoma With First-line Treatment FailureActive, not recruitingNCT04586088Phase 2
- Neoadjuvant PD-1 in Newly Diagnosed GlioblastomaStatus unknownNCT04583020Phase 2
- Camrelizumab Combined With Apatinib Mesylate Tablets and Nab-paclitaxel in the Second-line Treatment of Advanced Gastric CancerStatus unknownNCT04572542Phase 1/2
- TACE Combined With Camrelizumab and Apatinib in Intermediate and Advanced Hepatocelluar CarcinomaActive, not recruitingNCT04559607Not applicable
- Camrelizumab Combined With Apatinib in Patients With PD-1 Antagonists Resistant Recurrent/Metastatic Nasopharyngeal CarcinomaStatus unknownNCT04548271Phase 2
- Camrelizumab Combined With Apatinib in Patients With First-line Platinum-resistant Recurrent/Metastatic Nasopharyngeal CarcinomaStatus unknownNCT04547088Phase 2
- Neoadjuvant Camrelizumab, Nab-paclitaxel and Carboplatin in Stage IB-IIIA NSCLCStatus unknownNCT04541251Phase 2
- Induction Chemotherapy Combined With Camrelizumab in Locoregionally Advanced Hypopharyngeal CancerStatus unknownNCT04539600Phase 2
- First-line Nab-paclitaxel Plus Cisplatin Plus Camrelizumab in mTNBC PatientsCompletedNCT04537286Phase 2
- A Phase Ⅱ Clinical Trial of Camrelizumab for Adjuvant Treatment of Resectable Esophageal Squamous Cell CarcinomaStatus unknownNCT04533490Phase 2
- Camrelizumab Combined With Apatinib Mesylate for Perioperative Treatment of Resectable Hepatocellular CarcinomaActive, not recruitingNCT04521153Phase 2/3
- Neoadjuvant Chemotherapy With Camrelizumab in Locally Advanced Esophageal Squamous CellStatus unknownNCT04520035Phase 2
- Adjuvant Chemotherapy in Combination With Camrelizumab for Stage III Gastric Cancer (FOCUS-02)Active, not recruitingNCT04515615Phase 2
- A Clinical Study Of Camrelizumab With Or Without Radiotherapy In The Treatment Of Esophageal CancerStatus unknownNCT04512417Phase 2
- Combination of Metronomic Capecitabine With Camrelizumab for Treatment of Refractory Solid Tumor Trial (Cohort 2)Status unknownNCT04510818Phase 1
- Camrelizumab Plus Decitabine in Anti-PD-1 Treatment-naive Patients With Relapsed/Refractory Classical Hodgkin LymphomaStatus unknownNCT04510610Phase 2/3
- Combination of Metronomic Capecitabine With Camrelizumab for Treatment of Refractory Solid Tumor Trial (Cohort 1)Status unknownNCT04508686Phase 1
- Camrelizumab Combined With Apatinib in the Treatment of Epithelial Ovarian CancerStatus unknownNCT04507750Not applicable
- Camrelizumab in Combination With Neoadjuvant Chemotherapy for Resectable Thoracic Esophageal Squamous Cell CarcinomaActive, not recruitingNCT04506138Phase 1/2
- Efficacy and Safety of Camrelizumab Combined With Nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic CancerStatus unknownNCT04498689Phase 2
- Evaluation Effectiveness and Safety of (cTACE or DEB-TACE + FOLFOX Regimen HAIC) Combined With Camrelizumab and Apatinib Mesylas in the Treatment of Advanced Hepatocellular CarcinomaStatus unknownNCT04479527Phase 2
- Camrelizumab in Combination With Apatinib in Refractory and Relapsed DLBCLStatus unknownNCT04476459Phase 1/2
- Clinical Study of Camrelizumab Combined With APatinib and Albumin Paclitacxel in Patients With Advanced Lung AdenocarcinomaStatus unknownNCT04459078Phase 2
- A Study of Carilizumab in Combination With Apatinib in Subjects With Unresectable UPS and ASPSStatus unknownNCT04447274Phase 2
- Lenvatinib in Combination With Camrelizumab as First-Line Therapy in Patients With Advanced HCCStatus unknownNCT04443309Phase 1/2
- Camrelizumab Combined With Apatinib Mesylate for Head and Neck Squamous Cell CarcinomaStatus unknownNCT04440917Phase 2
- Study of Camrelizumab (SHR-1210) in Combination With Concurrent Chemoradiotherapy in Locally Advanced Esophageal CancerStatus unknownNCT04426955Phase 3
- Camrelizumab Combined With Apatinib Mesylate and Standard Chemotherapy (Pemetrixed + Carboplatin) in Patients With Tyrosine Kinase Inhibitor Failure in ALK-positive Advanced NSCLCStatus unknownNCT04425135Phase 2
- A Trial of Camrelizumab Combined With Ablation and Chemotherapy in Patients With Pancreatic Cancer Liver Metastasis（SHR-1210-HLJ-009）WithdrawnNCT04420130Not applicable
- The Combination of Camrelizumab and Apatinib as Second-line Therapy for Advanced Pancreatic CarcinomaStatus unknownNCT04415385Phase 2
- Clinical Control Study of Immunotherapy and Concurrent Chemoradiotherapy in Patients With Esophageal Cancer RecurrenceStatus unknownNCT04404491Phase 3
- Inductive Camrelizumab and Apatinib for Patients With Locally Advanced and Resectable Oral Squamous Cell CarcinomaCompletedNCT04393506Phase 1
- Camrelizumab Combined With CRT for Treatment of Patients With Local Recurrence of Esophageal CancerStatus unknownNCT04390945Phase 2
- Neoadjuvant PD-1 Antibody Plus Apatinib or Chemotherapy for Non-small Cell Lung CancerActive, not recruitingNCT04379739Phase 2
- Efficacy and Safety of Perioperative Chemotherapy Plus PD-1 Antibody in Gastric CancerStatus unknownNCT04367025Phase 2
- Molecularly Targeted Umbrella Study in Luminal Advanced Breast CancerStatus unknownNCT04355858Phase 2
- Combined PD1 Inhibitor and Decitabine in Elderly Patients With Relapse and Refractory Acute Myeloid LeukemiaStatus unknownNCT04353479Phase 2
- Comparison of MAPI+Camrelizumab Versus API+Apatinib Versus MAPI in Patients With a Poor Response to Preoperative Chemotherapy for Newly Diagnosed High-grade OsteosarcomaStatus unknownNCT04351308Phase 2
- Study to Evaluate the Efficacy and Safety of Camrelizumab and Famitinib in Patients With Advanced Solid TumorCompletedNCT04346381Phase 2
- Study of Camrelizumab (SHR-1210) vs. Chemotherapy in Participants With Relapsed or Refractory Classical Hodgkin LymphomaStatus unknownNCT04342936Phase 3
- Total Neoadjuvant Treatment Plus SHR1210 for High-risk Rectal Cancer and Biomarker Screening Base on NeoantigenStatus unknownNCT04340401Phase 2
- A Phase 3 Study Comparing Carelizumab Plus Nab-paclitaxel and Apatinib, Carelizumab Plus Nab-paclitaxel, and Nab-paclitaxel in Patients With Advanced Triple Negative Breast Cancer.TerminatedNCT04335006Phase 3
- A Phase II Trial of Camrelizumab in Combination With Apatinib and Eribulin in Patients With Advanced TNBCStatus unknownNCT04303741Phase 2
- Camrelizumab Combined With Endostar for First-line Treatment in Subjects With Advanced Squamous NSCLCStatus unknownNCT04303130Phase 2
- A Trial of SHR-1210 in Combination With AIN457 in Patients With MSS CRC（SHR-1210-AIN457）Status unknownNCT04298320Phase 1/2
- A Study of Camrelizumab As Consolidation Therapy After Radical Concurrent Chemoradiotherapy In Locally Advanced ESCCStatus unknownNCT04286958Phase 2
- Study of Anti-PD-1 Antibody Multimodal Combination as First-line Treatment on Time Window of Advanced Solid TumorStatus unknownNCT04282278Phase 2
- Camrelizumab in Combination With Apatinib Mesylate, Paclitaxel-albumin and S-1 for Translational Treatment of Gastric CancerStatus unknownNCT04258644Phase 2
- Camrelizumab(SHR-1210) Combined With GEMOX in Patients With Relapsed or Refractory Hodgkin LymphomaStatus unknownNCT04239170Phase 2
- Preoperative Short Course Radiotherapy With Chemotherapy and Camerelizumab in Locally Advanced Rectal CancerStatus unknownNCT04231552Phase 1/2
- Efficacy of Neoadjuvant PD-1 Blockade Plus Chemotherapy for Esophageal Squamous Cell CarcinomaCompletedNCT04225364Phase 2
- SHR-1210 Combined With Albumin-bound Paclitaxel and Epirubicin Neoadjuvant for Triple Negative Breast CancerStatus unknownNCT04213898Phase 1/2
- Camrelizumab With AC in Patients With Brain Metastases of Driven Gene-negative,NSCLCStatus unknownNCT04211090Phase 2
- Perioperative Treatment of Combined SOX With Apatinib and Camrelizumab for Oesophagogastric CancerActive, not recruitingNCT04208347Phase 2/3
- Camrelizumab Combined With Apatinib Mesylate or Camrelizumab Alone for First-line Treatment in Subjects With Programmed Death Ligand 1 (PD-L1) Positive Relapsed or Advanced Non-small Cell Lung Cancer (NSCLC)Status unknownNCT04203485Phase 3
- Camrelizumab Combined With Apatinib 、XELOX 、RFA in the Treatment of Liver Metastases of Colorectal CancerStatus unknownNCT04202978Phase 1/2
- Cryoablation Combined With Camrelizumab and Apatinib for Multiprimary Lung CancerStatus unknownNCT04201990Phase 1/2
- Camrelizumab Combined with Apatinib Mesylate Tablets, Nab-paclitaxel and S-1 in the Treatment of Locally Advanced Gastric CancerCompletedNCT04195828Phase 2
- Camrelizumab, Apatinib and Nab-paclitaxel as Second-line Treatment in Advanced Gastric CancerStatus unknownNCT04182724Phase 1/2
- PD-1 Antibody(SHR-1210) Plus Apatinib Combined With POF in Advanced Gastric CancerStatus unknownNCT04174339Not applicable
- A Study to Evaluate Camrelizumab in Combination With Nb-Paclitaxel in Patients With Advanced or Metastatic NSCLCStatus unknownNCT04167774Phase 2
- Induction Chemotherapy Combined With Immunotherapy for Locally Advanced Hypopharyngeal CarcinomaActive, not recruitingNCT04156698Phase 2
- A Study to Evaluate Camrelizumab in Combination With Docetaxel +S-1 as Adjuvant Treatment Therapy in Stage III Gastric CancerStatus unknownNCT04152889Phase 2
- Apatinib Combined With SHR-1210 Injection in the Treatment of Patients With Removable IB-IIIA NSCLCStatus unknownNCT04133337Phase 1/2
- Study of SHR-1210 Combined With Apatinib in the Treatment of SarcomaStatus unknownNCT04126993Phase 2
- A Study of SHR-1210 in Combination With Carboplatin+Paclitaxel-albumin in Subjects With Resectable NSCLCStatus unknownNCT04108013Phase 2
- Camrelizumab /Apatinib for Recurrent Platinum-resistant Ovarian CancerStatus unknownNCT04068974Phase 2
- Camrelizumab Combined With Apatinib in the Treatment of Patients With Advanced Gastric Cancer and Colorectal CancerStatus unknownNCT04067986Phase 1/2
- Camrelizumab Combined With AVD in the First-line Treatment for Patients With Advanced Classical Hodgkin's LymphomaActive, not recruitingNCT04067037Phase 2